Objectives Abdominal obesity is linked with a higher risk of developing ovarian cancer. However, the link between abdominal obesity and survival after diagnosis of ovarian cancer is unknown. The purpose of this study was to determine the impact of abdominal obesity on progression-free survival in patients with ovarian cancer.
Methods Among 258 patients, visceral and subcutaneous adipose tissue volume, along with perirenal adipose tissue thickness (a visceral adiposity proxy measure) was retrospectively measured from abdominal computed tomography (CT) scans obtained within 6 months of ovarian cancer diagnosis. Progression-free survival was computed using the Kaplan-Meier method and log-rank tests. Univariate and multivariate Cox proportional hazards analysis was used to determine relationships between measures of abdominal obesity and clinical variables in relation to progression-free survival.
Results Patients with perirenal adipose tissue thickness greater than 5 mm(median) had lower rates of progression-free survival at 5 years compared with patients with perirenal adipose tissue thickness less than 5 mm (45.6% vs 53.8%, respectively). Perirenal adipose tissue thickness less than 5 mm was associated with lower rates of progression-free survival on multivariate analysis (hazard ratio = 1.37; 95% confidence interval, 1.03–1.82). There was no correlation with other metrics of abdominal adiposity on progression-free survival in univariate or multivariate analysis.
Conclusions Our data suggest that perirenal adipose, but not body mass index, visceral, or subcutaneous fat volume that were measured within 6 months from diagnosis, is associated with lower rates of progression-free survival in ovarian cancer.
- Ovarian cancer
- Perirenal adipose tissue thickness
- Visceral adipose tissue
- Subcutaneous adipose tissue
- Body mass index
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
This study was supported by Ovarian Cancer Research fund (LT/MDACC/01.2011, by Dr Ann Klopp), American Cancer Society (RSG-14-159-01 by Dr Ann Klopp), and Cancer Prevention & Research Institute of Texas (CPRIT, RP140609, by Dr Ann Klopp).
This study was also supported by the Center for Energy Balance in Cancer Prevention and Survivorship, which is supported by the Duncan Family Institute for Cancer Prevention and Risk Assessment. In addition, research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under award number R25CA057730 (PI: Shine Chang, PhD).
The authors declare no conflicts of interest.
The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.